智通财经APP讯,翰森制药(03692)公布,于2026年2月12日,集团创新药甲磺酸阿美替尼片(中国商品名:阿美乐®,海外商品名:Aumseqa®)单药治疗已于欧盟获批上市,用于:(i)具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R) 置换突变的晚期非小细胞肺癌(NSCLC)成人患者的一线治疗,以及(ii)晚期 EGFR T790M突变阳性NSCLC成人患者的治疗。此次批准由欧盟委员会(EC)基于欧洲药品管理局(EMA)人用药品委员会(CHMP)的积极意见作出。
智通财经APP讯,翰森制药(03692)公布,于2026年2月12日,集团创新药甲磺酸阿美替尼片(中国商品名:阿美乐®,海外商品名:Aumseqa®)单药治疗已于欧盟获批上市,用于:(i)具有表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R) 置换突变的晚期非小细胞肺癌(NSCLC)成人患者的一线治疗,以及(ii)晚期 EGFR T790M突变阳性NSCLC成人患者的治疗。此次批准由欧盟委员会(EC)基于欧洲药品管理局(EMA)人用药品委员会(CHMP)的积极意见作出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.